Bob Shin

Bob Shin is a Managing Director with Premier Partners. He is an investor and entrepreneur with over 20 years of experience focused on the investigation and development of biotechnology and pharmaceuticals, especially from a cross-border transaction perspective. Prior to joining Premier Partners, Mr. Shin was a Korea country head of Palo Alto Investors and Burrill & Company. Since joining Premier Partners in 2016, he has played a significant role in managing the healthcare-centric fund. In addition to Aardvark Therapeutics, Mr. Shinis a Director of Yuhan USA, which is a subsidiary of Yuhan(KRX 000100), ImmuneOncia, JUVIC, Korea Prime Pharma. Mr. Shin has participated in a number of other Premier Partners healthcare portfolio companies including Blackthorn, Faraday, Tium(KOSDAQ 321550), Knotus(KOSDAQ 278650), Icure Pharm(KOSDAQ 175250), and PH Pharma. Mr. Shin holds an M.B.A. from Colorado State University, an M.A. and a B.S. in biotechnology from Yonsei University in Korea.